Literature DB >> 9549720

Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease.

I L Notkola1, R Sulkava, J Pekkanen, T Erkinjuntti, C Ehnholm, P Kivinen, J Tuomilehto, A Nissinen.   

Abstract

The epsilon 4 allele of the apolipoprotein E (apoE) is associated with Alzheimer's disease (AD) and also with elevated serum total cholesterol and low-density lipoprotein levels. However, the interrelationships between apoE genotype, plasma cholesterol levels and AD risk have been studied very little. We examined the possible role of serum total cholesterol in the pathogenesis of AD in a population-based sample of 444 men, aged 70-89 years, who were survivors of the Finnish cohorts of the Seven Countries Study. Previous high serum cholesterol level (mean level > or = 6.5 mmol/l) was a significant predictor of the prevalence of AD (odds ratio = 3.1; 95% confidence interval = 1.2, 8.5) after controlling for age and the presence of apoE epsilon 4 allele. In men who subsequently developed AD the cholesterol level decreased before the clinical manifestations of AD. We conclude that high serum total cholesterol may be an independent risk factor for AD and some of the effect of the apoE epsilon 4 allele on risk of AD might be mediated through high serum cholesterol.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9549720     DOI: 10.1159/000026149

Source DB:  PubMed          Journal:  Neuroepidemiology        ISSN: 0251-5350            Impact factor:   3.282


  184 in total

1.  Association of aortic atherosclerosis with cerebral beta-amyloidosis and learning deficits in a mouse model of Alzheimer's disease.

Authors:  Ling Li; Dongfeng Cao; David W Garber; Helen Kim; Ken-ichiro Fukuchi
Journal:  Am J Pathol       Date:  2003-12       Impact factor: 4.307

2.  Links between the pathology of Alzheimer's disease and vascular dementia.

Authors:  Marcin Sadowski; Joanna Pankiewicz; Henrieta Scholtzova; Yong-sheng Li; David Quartermain; Karen Duff; Thomas Wisniewski
Journal:  Neurochem Res       Date:  2004-06       Impact factor: 3.996

Review 3.  Diet and Alzheimer's disease: what the evidence shows.

Authors:  Martha Clare Morris
Journal:  MedGenMed       Date:  2004-01-15

4.  ApoAI deficiency results in marked reductions in plasma cholesterol but no alterations in amyloid-beta pathology in a mouse model of Alzheimer's disease-like cerebral amyloidosis.

Authors:  Anne M Fagan; Erin Christopher; Jennie W Taylor; Maia Parsadanian; Michael Spinner; Melanie Watson; John D Fryer; Suzanne Wahrle; Kelly R Bales; Steven M Paul; David M Holtzman
Journal:  Am J Pathol       Date:  2004-10       Impact factor: 4.307

Review 5.  Perimenopause and cognition.

Authors:  Gail A Greendale; Carol A Derby; Pauline M Maki
Journal:  Obstet Gynecol Clin North Am       Date:  2011-09       Impact factor: 2.844

Review 6.  Dyslipidemia and dementia: current epidemiology, genetic evidence, and mechanisms behind the associations.

Authors:  Christiane Reitz
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

Review 7.  Anti-dementia drugs and hippocampal-dependent memory in rodents.

Authors:  Carla M Yuede; Hongxin Dong; John G Csernansky
Journal:  Behav Pharmacol       Date:  2007-09       Impact factor: 2.293

8.  Near-infrared spectroscopy (NIRS) and vagus somatosensory evoked potentials (VSEP) in the early diagnosis of Alzheimer's disease: rationale, design, methods, and first baseline data of the Vogel study.

Authors:  Thomas Polak; Martin J Herrmann; Laura D Müller; Julia B M Zeller; Andrea Katzorke; Matthias Fischer; Fabian Spielmann; Erik Weinmann; Leif Hommers; Martin Lauer; Andreas J Fallgatter; Jürgen Deckert
Journal:  J Neural Transm (Vienna)       Date:  2017-09-01       Impact factor: 3.575

9.  Age-related influence of the HDL receptor SR-BI on synaptic plasticity and cognition.

Authors:  Eric H Chang; Attilio Rigotti; Patricio T Huerta
Journal:  Neurobiol Aging       Date:  2007-08-23       Impact factor: 4.673

Review 10.  Dyslipidemia and the risk of Alzheimer's disease.

Authors:  Christiane Reitz
Journal:  Curr Atheroscler Rep       Date:  2013-03       Impact factor: 5.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.